New drug RPT1G enters early human testing for tough blood cancers
Disease control
Recruiting now
This early-stage study is testing a new drug called RPT1G in 24 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) have not responded to standard treatments or have returned. The main goals are to see if the drug is safe and to find the best do…
Phase: PHASE1 • Sponsor: Remedy Plan, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC